Page last updated: 2024-11-02

perphenazine and Cognition Disorders

perphenazine has been researched along with Cognition Disorders in 4 studies

Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.
perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.

Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.

Research Excerpts

ExcerptRelevanceReference
"363 hospital-based psychiatric patients in India, Romania, and United States aged 18 to 65 years and meeting criteria for DSM-IV-TR diagnosis of chronic schizophrenia were randomized double-blind to receive BL-1020 10 mg/d, BL-1020 20-30 mg/d, placebo, or risperidone (2-8 mg/d) for 6 weeks."5.16Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study. ( Anand, R; Davidson, M; Geffen, Y; Keefe, R; Rabinowitz, J, 2012)
"Randomized, double-blind study of patients with schizophrenia assigned to receive treatment with olanzapine, perphenazine, quetiapine fumarate, or risperidone for up to 18 months as reported previously by Lieberman et al."5.12Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. ( Bilder, RM; Capuano, G; Davis, CE; Davis, SM; Gold, JM; Green, MF; Harvey, PD; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Meltzer, HY; Palmer, BW; Perkins, DO; Rosenheck, RA; Stroup, TS; Swartz, MS, 2007)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Crespo-Facorro, B1
Rodríguez-Sánchez, JM1
Pérez-Iglesias, R1
Mata, I1
Ayesa, R1
Ramirez-Bonilla, M1
Martínez-Garcia, O1
Vázquez-Barquero, JL1
Yolken, RH1
Torrey, EF1
Lieberman, JA2
Yang, S1
Dickerson, FB1
Geffen, Y1
Keefe, R1
Rabinowitz, J1
Anand, R1
Davidson, M1
Keefe, RS1
Bilder, RM1
Davis, SM1
Harvey, PD1
Palmer, BW1
Gold, JM1
Meltzer, HY1
Green, MF1
Capuano, G1
Stroup, TS1
McEvoy, JP1
Swartz, MS1
Rosenheck, RA1
Perkins, DO1
Davis, CE1
Hsiao, JK1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Double Blind Placebo Controlled Study of Valaciclovir in Treatment of Psychosis in Patients With Schizophrenia[NCT01364792]Phase 224 participants (Actual)Interventional2011-04-30Completed
A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study to Determine the Efficacy, Tolerability and Safety of Low and High Non-overlapping Dose Ranges of BL-1020 Compared to Placebo and Risperidone[NCT00567710]Phase 2360 participants (Anticipated)Interventional2008-07-31Completed
Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis[NCT02634684]Phase 282 participants (Actual)Interventional2014-07-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

MATRICS Consensus Cognitive Battery Performance (MCCB)

The T-score indicates the performance on a neurocognitive battery of tests. Higher score reflects better performance. (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours

,,,
Interventionstandardized T-score (Mean)
placeboamphetamine
Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo57.87056.000
Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine54.47655.476
Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo39.89538.105
Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine31.89533.842

Prepulse Inhibition (PPI)

"PPI was assessed with 42 trials of 6 types: 118 dB 40 ms pulse alone (P) & the same P preceded 10, 20, 30, 60, or 120 ms by a prepulse (pp) 16 dB over background. Startle magnitude (SM), habituation, latency & latency facilitation were measured to interpret changes in PPI.~%PPI = 100 x [(SM on P trials) - (SM on pp+P trials)] / SM on P trials. Example:~SM on P trials = 80 units SM on pp+P trials = 30 units %PPI = 100 x (80-30)/80 = 100 x 50/80 = 62.5%~Greater %PPI mean the reflex has been inhibited to a greater extent in the presence of a pp.~%PPI can't exceed 100: when SM on pp+P trials = 0, then %PPI = 100 x (SM on P trials - 0)/SM on P trials = 100 x 1 = 100%.~However, %PPI can theoretically be infinitely negative since SM on pp+P trials could be infinitely large (prepulse facilitiation (PPF)), i.e. SM is potentiated in the presence of a pp. PPF is normal at very short & very long pp intervals, but not within a species-specific physiological range of intervals." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours

,,,
Intervention% inhibition of startle (Mean)
PlaceboAmphetamine
Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo50.62653.029
Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine50.62645.822
Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo41.16239.545
Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine22.62932.656

Targeted Cognitive Training (TCT): PositScience, Inc.

"Auditory discrimination learning: Subjects identify direction (up vs. down) of 2 consecutive sound sweeps. Parameters (e.g. inter-sweep interval, sweep duration) are established for subjects to maintain 80% correct responses. On screen and test days, subjects complete 1h of TCT. Analytic software yields the key measures: auditory processing speed (APS) and APS learning. APS is the shortest inter-stimulus interval at which a subject performs to criteria and APS learning is the difference (ms) between the first APS and the best APS of the subsequent trials. A smaller APS reflects better discrimination (i.e., subject correctly identified frequency sweep direction despite a smaller ms gap between stimuli) and a larger ms value for APS learning reflects more learning, i.e., faster APS with repeated trials. Limits for APS are capped at 0-to-1000 ms; values for APS learning are capped at (-) 1000-to-APS." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours

,,,
Interventionmsec (Mean)
placeboamphetamine
Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo-2.11329.190
Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine5.91135.905
Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo-50.158101.000
Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine-15.11852.647

Trials

4 trials available for perphenazine and Cognition Disorders

ArticleYear
Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.
    The Journal of clinical psychiatry, 2009, Apr-21, Volume: 70, Issue:5

    Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Cognition Disorders; Fe

2009
Serological evidence of exposure to Herpes Simplex Virus type 1 is associated with cognitive deficits in the CATIE schizophrenia sample.
    Schizophrenia research, 2011, Volume: 128, Issue:1-3

    Topics: Analysis of Variance; Antibodies, Viral; Antipsychotic Agents; Cognition Disorders; Double-Blind Met

2011
Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study.
    The Journal of clinical psychiatry, 2012, Volume: 73, Issue:9

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cognition Disorders; Dopamine Antagonists; Double-Bli

2012
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Archives of general psychiatry, 2007, Volume: 64, Issue:6

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Cohort Studies; Dibenzothiazepine

2007